Kennedy, N. A., Goodhand, J. R., Bewshea, C., Nice, R., Chee, D., Lin, S., Chanchlani, N., Butterworth, J., Cooney, R., Croft, N. M., Hart, A. L., Irving, P. M., Kok, K. B., Lamb, C. A., Limdi, J. K., Macdonald, J., McGovern, D. P., Mehta, S. J., Murray, C. D., Patel, K. V., Pollok, R. C., Raine, T., Russell, R. K., Selinger, C. P., Smith, P. J., Bowden, J., McDonald, T. J., Lees, C. W., Sebastian, S., Powell, N., & Ahmad, T. (2021). anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865–875. http://access.bl.uk/ark:/81055/vdc_100127562043.0x000063